Literature DB >> 32355665

Nanoparticles in Gastrooncology.

André Jefremow1, Markus F Neurath1.   

Abstract

BACKGROUND: Gastrointestinal malignancies have the greatest incidence and cancer-associated death rates worldwide. Routine therapeutic modalities include surgery, chemotherapy and radiation but they often fail to reach the goal of cancer-free survival.
SUMMARY: In the light of this urgent medical need for the treatment of GI tumors, nanotech-nology-based approaches, i.e. nanomedicine, promise new therapeutic options. Using nanoparticles instead of classically designed drugs, targeting anticancer agents directly to the tumor site may revolutionize both diagnostic and therapeutic tools thereby facilitating the identification and elimination of malignant cells. Importantly, diagnostic insight and therapeutic effects can be achieved simultaneously through the same nanoparticle. Additionally, a nanoparticle may be loaded with more than one agent, thereby further increasing the value and power of the nanotechnology approach in oncologic therapeutic concepts. Although most insight into mechanisms of nanomedicine has been gained from in vitro and preclinical in vivo models, few clinical trials have been conducted, and nanomedicine-based concepts are already part of standard treatment algorithms. However, despite substantial progress it remains a challenge to design nanoparticles that feature all desirable characteristics at the same time. KEY MESSAGES: This review seeks to provide substantial insight into the current status of nanomedicine-based approaches employed for diagnostic and/or therapeutic purposes in the field of gastrointestinal cancers by highlighting achievements and pointing out unresolved issues that need to be further addressed by future research attempts.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Gastrointestinal tumors; Gastrooncology; Nanomedicine; Nanoparticles

Year:  2020        PMID: 32355665      PMCID: PMC7184848          DOI: 10.1159/000506908

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  59 in total

Review 1.  Magnetic nanoparticles: In vivo cancer diagnosis and therapy.

Authors:  Michele K Lima-Tenório; Edgardo A Gómez Pineda; Nasir M Ahmad; Hatem Fessi; Abdelhamid Elaissari
Journal:  Int J Pharm       Date:  2015-07-29       Impact factor: 5.875

2.  Pro-MMP-9 is associated with poor prognosis in gastric cancer.

Authors:  Yukihiro Nomura; Kunika Takasaki; Masakazu Tada; Masataka Yoshimoto; Hideyuki Ishida; Nobuo Murata; Shunichiro Kubota
Journal:  Scand J Gastroenterol       Date:  2007-09       Impact factor: 2.423

3.  Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.

Authors:  P J Julyan; L W Seymour; D R Ferry; S Daryani; C M Boivin; J Doran; M David; D Anderson; C Christodoulou; A M Young; S Hesslewood; D J Kerr
Journal:  J Control Release       Date:  1999-02-22       Impact factor: 9.776

4.  Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer.

Authors:  Fang-Bo Cui; Ru-Tian Li; Qin Liu; Pu-Yuan Wu; Wen-Jing Hu; Guo-Feng Yue; Hui Ding; Li-Xia Yu; Xiao-Ping Qian; Bao-Rui Liu
Journal:  Cancer Lett       Date:  2013-12-11       Impact factor: 8.679

Review 5.  Gold nanoparticles in theranostic oncology: current state-of-the-art.

Authors:  Sohail Akhter; Mohammad Zaki Ahmad; Farhan Jalees Ahmad; Gert Storm; Robbert J Kok
Journal:  Expert Opin Drug Deliv       Date:  2012-08-16       Impact factor: 6.648

6.  Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy.

Authors:  Peng Huang; Jing Lin; Xiansong Wang; Zhe Wang; Chunlei Zhang; Meng He; Kan Wang; Feng Chen; Zhiming Li; Guangxia Shen; Daxiang Cui; Xiaoyuan Chen
Journal:  Adv Mater       Date:  2012-06-21       Impact factor: 30.849

7.  Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy.

Authors:  Peng Huang; Zhiming Li; Jing Lin; Dapeng Yang; Guo Gao; Cheng Xu; Le Bao; Chunlei Zhang; Kan Wang; Hua Song; Hengyao Hu; Daxiang Cui
Journal:  Biomaterials       Date:  2011-05       Impact factor: 12.479

8.  Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on "oxidation therapy".

Authors:  Xiaolin Li; Xiaowei Lu; Huae Xu; Zhenshu Zhu; Haitao Yin; Xiaoping Qian; Rutian Li; Xiqun Jiang; Baorui Liu
Journal:  Mol Pharm       Date:  2011-12-29       Impact factor: 4.939

9.  Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.

Authors:  Chitta Ranjan Patra; Resham Bhattacharya; Enfeng Wang; Aaron Katarya; Julie S Lau; Shamit Dutta; Michael Muders; Shanfeng Wang; Sarah A Buhrow; Stephanie L Safgren; Michael J Yaszemski; Joel M Reid; Matthew M Ames; Priyabrata Mukherjee; Debabrata Mukhopadhyay
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

10.  N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice.

Authors:  L W Seymour; K Ulbrich; S R Wedge; I C Hume; J Strohalm; R Duncan
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.